3vdd: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
<StructureSection load='3vdd' size='340' side='right' caption='[[3vdd]], [[Resolution|resolution]] 3.20Å' scene=''> | <StructureSection load='3vdd' size='340' side='right' caption='[[3vdd]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3vdd]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3vdd]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Hrv-2 Hrv-2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VDD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3VDD FirstGlance]. <br> | ||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BT8:3-ETHOXY-6-{2-[1-(6-METHYLPYRIDAZIN-3-YL)PIPERIDIN-4-YL]ETHOXY}-1,2-BENZOXAZOLE'>BT8</scene><br> | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BT8:3-ETHOXY-6-{2-[1-(6-METHYLPYRIDAZIN-3-YL)PIPERIDIN-4-YL]ETHOXY}-1,2-BENZOXAZOLE'>BT8</scene><br> | ||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3vdd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vdd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3vdd RCSB], [http://www.ebi.ac.uk/pdbsum/3vdd PDBsum]</span></td></tr> | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3vdd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vdd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3vdd RCSB], [http://www.ebi.ac.uk/pdbsum/3vdd PDBsum]</span></td></tr> | ||
<table> | <table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use. We have developed a potent, orally available rhinovirus inhibitor 6 that has progressed through early clinical trials. The compound shows favorable pharmacokinetic and activity profiles and has a confirmed mechanism of action through crystallographic studies of a rhinovirus-compound complex. The compound has now progressed to phase IIb clinical studies of its effect on natural rhinovirus infection in humans. | |||
An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.,Feil SC, Hamilton S, Krippner GY, Lin B, Luttick A, McConnell DB, Nearn R, Parker MW, Ryan J, Stanislawski PC, Tucker SP, Watson KG, Morton CJ ACS Med Chem Lett. 2012 Feb 13;3(4):303-7. doi: 10.1021/ml2002955. eCollection, 2012 Apr 12. PMID:24900468<ref>PMID:24900468</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
==See Also== | |||
*[[Human rhinovirus|Human rhinovirus]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Hrv-2]] | ||
[[Category: Feil, S C.]] | [[Category: Feil, S C.]] | ||
[[Category: Morton, C J.]] | [[Category: Morton, C J.]] | ||